pelvic floor muscle training was suggestive of benefit at three months but it is not known if this was sustained, and the treatment was associated with high levels of postoperative retention and dysuria. Greater symptomatic improvement was observed with surgical treatments, though the advantages need to be set against likely higher risks. No clear-cut conclusions could be drawn from trials comparing alternative agents, although dextranomer hyaluronic acid was associated with more local side effects and is no longer commercially available for this indication. There is insufficient evidence to show superiority of mid-urethral or bladder neck injection. The single trial of autologous fat provides a reminder that periurethral injections can occasionally cause serious side effects.Editorial Comment: This is an updated review of an analysis of periurethral injection therapy originally published in 2007 by the same group. Readers should be aware of the fact that Contigen® (glutaraldehyde cross-linked bovine collagen), previously available from Bard®, is no longer manufactured. I had our drug information people confirm this with Bard. Bard recommends another company that they say has a "similar product." The bottom line regarding this Cochrane Collaboration seems to be expressed under "implications for practice": "The lack of long-term followup and health economic data means that at present, injection therapy cannot be recommended as an alternative therapy for women fit for other surgical procedures. Reported outcomes are variable and at times poor, and the finding of a placebo response in a single trial means that comment concerning the usefulness of injection therapy as a first-line option is not evidencebased. For women with extensive co-morbidity precluding anesthesia, injection therapy may represent a useful option for relief of symptoms, at least for a 12-month period. The patient and healthcare provider should know that two or three injection sessions may be required and a satisfactory result is not guaranteed." Acta Obstet Gynecol Scand 2011; 90: 815-824. Stress urinary incontinence is a common disorder affecting the quality of life for millions of women worldwide. Effective surgical procedures involving synthetic permanent meshes exist, but significant short-and long-term complications occur. Cell-based therapy using autologous stem cells or progenitor cells presents an alternative approach, which aims at repairing the anatomical components of the urethral continence mechanism. In vitro expanded progenitor cells isolated from muscle biopsies have been most intensely investigated, and both preclinical trials and a few clinical trials have provided proof of concept for the idea. An initial enthusiasm caused by positive results from early clinical trials has been dampened by the recognition of scientific irregularities. At the same time, the safety issue for cell-based therapy has been highlighted by the appearance of new and comprehensive regulatory demands. The influence on the cost effectiveness, the clinical...